WS Investor
09 Mar 2026, 22:17
Pfizer reported positive Phase 2 trial results for its investigational trispecific antibody tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis, meeting the study’s primary endpoint.
The treatment significantly increased the share of patients achieving a 75% reduction in eczema severity (EASI-75) after 16 weeks compared with placebo, with response rates of 38.7%, 51.9% and 49.4% across tested doses. The drug was generally well tolerated, with adverse event rates similar to placebo.
Tilrekimig targets three inflammatory pathways—IL-4, IL-13 and TSLP—and could become a first-in-class once-monthly therapy for multiple Type-2 inflammatory diseases, including atopic dermatitis, asthma and COPD. Pfizer said it plans to advance the therapy into Phase 3 development later this year.
Source: Business Wire
The treatment significantly increased the share of patients achieving a 75% reduction in eczema severity (EASI-75) after 16 weeks compared with placebo, with response rates of 38.7%, 51.9% and 49.4% across tested doses. The drug was generally well tolerated, with adverse event rates similar to placebo.
Tilrekimig targets three inflammatory pathways—IL-4, IL-13 and TSLP—and could become a first-in-class once-monthly therapy for multiple Type-2 inflammatory diseases, including atopic dermatitis, asthma and COPD. Pfizer said it plans to advance the therapy into Phase 3 development later this year.
Source: Business Wire